ADMA ADMA BIOLOGICS, INC.
8-K Current Report
Filed: February 25, 2026
Health Care
Biological Products, (No Diagnostic Substances)ADMA BIOLOGICS, INC. (ADMA) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 5.02: Departure/Election of Directors or Officers
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4/full-year 2025 earnings release filed February 25, 2026 — refer to Exhibit 99.1 for actual financial results
- • Signed by CEO Adam S. Grossman, indicating standard executive authorization of the disclosure
Item 5.02 · Departure/Election of Directors or Officers
- • CFO Brad Tade retiring Feb 25, 2026 post-10-K filing; transitioning to consulting at $41,667/month through July 31, 2026
- • Successor Terry Kohler, age 48, promoted from Executive Financial Advisor; prior CFO roles at OptiNose and Verrica Pharmaceuticals
Other ADMA BIOLOGICS, INC. 8-K Filings
Get deeper insights on ADMA BIOLOGICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.